Key Highlights

  • NRC Health (NASDAQ:NRC) is scheduled to report third-quarter results after the close on Tuesday, October 27, 2026, with consensus earnings of USD 0.21 per share.
  • Second-quarter revenue rose 4% to USD 35.4 million, while total recurring contract value rose 11% to USD 151.9 million, the figure investors tend to follow most closely.
  • A second-quarter GAAP loss of USD 0.15 per share reflected accelerated stock vesting and cash bonuses, and adjusted earnings were USD 0.31 per share on adjusted EBITDA of USD 9.4 million.
  • The company gives no formal financial guidance, so management commentary on bookings and the strongest Governance Institute sales in seven years is the main read-across for NRC Health (NASDAQ:NRC).

NRC Health (NASDAQ:NRC): a USD 0.21 bar after a distorted quarter

NRC Health (NASDAQ:NRC) sells subscription analytics that measure patient and member experience for hospitals and other care providers, and it is scheduled to report after the close on Tuesday, October 27, 2026. Consensus earnings are USD 0.21 per share. In the second quarter, reported on Tuesday, July 28, 2026, revenue was USD 35.4 million, up 4% from USD 34.0 million. Operating income was a loss of USD 3.2 million against a profit of USD 1.6 million a year earlier, and the GAAP net loss was USD 3.3 million, or USD 0.15 per share. Adjusted earnings were USD 0.31 per share, with adjusted EBITDA of USD 9.4 million, or 27% of revenue. Free cash flow was USD 0.1 million. Results cannot be known in advance.

Why Recurring Contract Value Sets the Tone

The company sells annual contracts, so total recurring contract value, the annualised value of subscriptions in force, shows future revenue more clearly than a single quarter. It reached USD 151.9 million in the second quarter, up 11% year on year. Chief executive Trent Green cited double-digit growth and the strongest bookings in seven years for The Governance Institute, a board education unit, and said the company was positioned for a strong second half. The second-quarter loss came from accelerated stock vesting and related cash bonuses of about USD 2.9 million that the company excludes from adjusted figures. Because the estimate of USD 0.21 sits below the adjusted USD 0.31, investors will check whether the basis is GAAP or adjusted. A quarterly dividend of USD 0.16 was payable on Friday, October 9, 2026.

Risks and What to Watch

The bull case is recurring contract value growth held near or above 11%, margins returning toward the prior profit level as the vesting charges drop out and a confirmation of the strong second half, which could support the shares. The bear case is slower bookings, further cost pressure in operating income or a quarter in which revenue growth stays near 4% while expenses rise, which would challenge the premium that subscription businesses command. The shares fell after the second-quarter report despite the contract value growth, which shows how sensitive the reaction is to margins. With no guidance, the call matters. Investors should watch contract value, adjusted EBITDA margin, cash flow and any comment on renewals and hospital budgets.

Where Things Stand

The answer is that NRC Health (NASDAQ:NRC) can clear a USD 0.21 estimate on adjusted figures if the one-off charges do not repeat, but the reaction will rest on recurring contract value and margins. The next catalysts are the report after the close on Tuesday, October 27, 2026, the Federal Reserve decision on Wednesday, October 28, 2026 and fourth-quarter bookings commentary. Estimates, bookings and costs can change, no guidance is provided, and this is not investment advice.